Avecho Biotechnology Ltd. engages in the development, production, sale, and licensing of products incorporating its patented platform technology, Targeted Penetration Matrix (TPM), for the pharmaceutical, skin care and animal health and nutrition industries. It operates through the following business segments: Production and Personal Care; Human Health; and All Other. The Production and Personal Care segment manufactures and sells TPM and Vital ET. The Human Health segment covers delivery of drugs through gels, injectables, and patches. The All Other segments involves the BioElixia division. The company was founded on June 19, 1992 and is headquartered in Clayton, Australia.